In the single-arm, multicenter, phase II part of the CAVALLI trial, the researchers analyzed the efficacy of 800-mg venetoclax plus R-CHOP in all first-line DLBCL patients.
Naveed Saleh, MD, MS
Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.
Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.
Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.
Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.
Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.
Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.
Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.
Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.